15.2 First-Episode Psychosis, Schizophrenia, and Antipsychotic Prescribing and Adverse Effects
Key Takeaways
Assess first-episode psychosis promptly, including onset, collateral history, mood and substance exposure, risk and physical findings. Select investigations based on the suspected cause and arrange early specialist care.
Schizophrenia diagnosis depends on the framework. ICD-11 generally requires at least one month of qualifying symptoms. DSM-5 requires six months of continuous disturbance with an active phase and functional decline.
Sustained spasm suggests dystonia, an urge to move suggests akathisia, slowing and rigidity suggest parkinsonism, and delayed involuntary orofacial movements suggest tardive dyskinesia. Assess the airway promptly in acute dystonia.
Suspect neuroleptic malignant syndrome with compatible dopamine-blocking exposure, rigidity, hyperthermia, altered consciousness and autonomic instability. Stop dopamine blockers and give urgent monitored support. Specialist adjuncts depend on severity.
Use the current Irish clozapine product and monitoring service for ANC thresholds and follow-up. Fever or sore throat needs immediate assessment and ANC testing. Also watch for myocarditis, severe bowel hypomotility and seizures.
First-Episode Psychosis and the Clinical Assessment
A person with first-episode psychosis may report voices, fixed false beliefs or experiences of being controlled. They may also show disorganised speech or behaviour. Ask when these symptoms first appeared, using collateral information with consent where possible. The HSE early intervention in psychosis model aims to shorten the time between the onset of psychosis and effective treatment. Arrange prompt specialist mental health assessment through the local pathway. Immediate risk to self or others, inability to meet basic needs or suspected acute physical illness requires emergency assessment.
Some people have weeks or months of changes before overt psychosis, such as social withdrawal, difficulty at work or school, reversed sleep rhythm or fleeting unusual perceptions. Others present abruptly. Record the onset, functional change, medication and substance exposure including recent withdrawal, accompanying mood symptoms, and any prior episodes. Assess mental state, suicidality, vulnerability and risk to others. Examine the patient physically, including vital signs and a focused neurological examination.
Use findings to select tests
| Finding | What it changes |
|---|---|
| Fluctuating awareness or inattention, fever or abnormal vital signs | Consider delirium or other acute illness. Check bedside glucose promptly if consciousness is impaired and select further tests for suspected infection, metabolic disturbance, toxicity or withdrawal. |
| Clear intoxication or withdrawal history | Ask family or carers about timing and exposure. Toxicology may help when it will change care. A routine urine screen has limited coverage and detection windows. |
| New focal deficit, head injury, seizure or rapidly changing cognition | Consider structural or epileptic causes and assess the need for urgent imaging or EEG. NICE CG178 advises against routine structural neuroimaging for every first presentation. |
| Subacute psychiatric and cognitive change with seizures, dyskinesia or autonomic instability | Suspect encephalitis, including anti-NMDA receptor encephalitis, and seek urgent medical and neurological assessment for appropriate MRI, EEG and CSF investigation. |
| Tremor or other movement changes plus otherwise unexplained liver disease in a young adult | Consider Wilson disease and arrange targeted investigation with specialist input. |
| Systemic symptoms, medication exposure or relevant infection risk | Choose appropriate tests such as blood count, renal and liver tests, electrolytes, calcium, thyroid function or specific infectious tests according to the suspected cause. |
Worked example. A student becomes withdrawn over several months and describes hearing running commentary. A short turn in the interview with no fever does not establish a diagnosis. Check the timeline, functioning, exposure history, mood and risk, then refer promptly. New fever, fluctuating attention and a witnessed seizure would change the priority to urgent medical assessment for an acute cerebral or systemic cause.
Diagnostic Criteria of Schizophrenia and Psychopathology
Schizophrenia is a severe neuropsychiatric disorder characterized by profound disturbances in perception, thinking, volition, and emotional expression. Diagnostic confirmation relies on standardized diagnostic systems (DSM-5 and ICD-11).
Duration and required symptoms
- DSM-5 requires at least two of delusions, hallucinations, disorganised speech, grossly disorganised or catatonic behaviour and negative symptoms. At least one is delusions, hallucinations or disorganised speech. The active phase lasts at least one month unless shortened by successful treatment, within at least six months of continuous disturbance. DSM-5 also requires substantial loss of function in a major area or a failure to attain expected functioning if onset is in childhood or adolescence.
- ICD-11 requires at least two qualifying symptoms present most of the time for at least one month. At least one is persistent delusions, persistent hallucinations, disorganised thinking or an experience of influence, passivity or control. Functional impairment is common and informs care, while the formal diagnostic requirements do not require it.
- In either system, look for medical and substance causes. Establish whether psychosis occurs only within a mood episode and use the chosen classification's criteria for mood disorders with psychotic features and schizoaffective disorder.
Worked example. Five months of persistent hallucinations and persecutory delusions without a mood, substance or medical explanation can meet the ICD-11 symptom and duration requirements. In DSM-5 this duration is too short for schizophrenia. Assess DSM-5 schizophreniform disorder if its other criteria are met and start care promptly.
Schneiderian first-rank symptoms
These are historical descriptions of particular experiences. Elicit what the person means before naming the symptom. These experiences can occur in other disorders.
- Auditory Hallucinations:
- Third-Person Auditory Hallucinations: Voices discussing, debating, or arguing about the patient in the third person (e.g., "he is useless, he cannot do anything right").
- Running Commentary: A voice narrating the patient's ongoing actions, movements, or thoughts in real time (e.g., "he is now walking to the door; he is opening the fridge").
- Thought Echo (Gedankenlautwerden): The patient experiences their own thoughts being spoken aloud, heard as an auditory perception simultaneously with or immediately after the thought arises.
- Thought Alienation (Delusions of Thought Interference):
- Thought Insertion: The delusional conviction that external thoughts are being placed directly into the patient's mind by an outside agency, alien entity, or foreign device.
- Thought Withdrawal: The delusion that the patient's thoughts are being actively removed, extracted, or stolen from their head by an external force.
- Thought Broadcasting: The unshakeable belief that the patient's private thoughts are radiating outward or being telepathically transmitted so that everyone in the vicinity can hear or experience them.
- Passivity Phenomena (Delusions of Control):
- The patient experiences their thoughts, feelings, bodily impulses, or motor volitions as being externally imposed, controlled, and manipulated by an outside entity:
- Passivity of affect: Experiencing feelings forced upon them from outside.
- Passivity of volition: Feeling compelled to perform motor actions as an automaton.
- Somatic passivity: Experiencing bodily sensations (pain, electricity, sexual arousal) caused by an external machine or influence.
- The patient experiences their thoughts, feelings, bodily impulses, or motor volitions as being externally imposed, controlled, and manipulated by an outside entity:
- Delusional Perceptions:
- A two-stage phenomenon where a real, normal sensory perception is instantaneously interpreted with a bizarre, idiosyncratic, self-referential meaning that cannot be derived logically from the event (e.g., seeing an ordinary red postbox and immediately knowing that one has been selected by foreign intelligence to rule the nation).
Positive vs Negative Symptom Clusters
Understanding the dichotomy between positive and negative symptoms is essential for therapeutic planning:
- Positive symptoms add or distort mental experiences, as with delusions, hallucinations and disorganised thinking. Antipsychotics often help positive symptoms. Dopaminergic models help explain some effects at a population level.
- Negative symptoms represent diminished function. The five A's are:
- Avolition: Profound apathy, lack of initiative, and inability to initiate or sustain goal-directed activities.
- Anhedonia: Inability to anticipate or experience pleasure from formerly rewarding activities.
- Alogia: Poverty of speech, manifested as markedly reduced spontaneous speech output or impoverished semantic content.
- Affective Flattening: Immobility of facial expression, poor eye contact, blunted emotional vocal inflection, and reduced body language.
- Asociality: Lack of interest in social interactions, leading to progressive social withdrawal and isolation.
Assess whether depression, sedation, active psychosis or drug-induced parkinsonism is contributing to apparent negative symptoms. Persistent primary negative symptoms can impair longer-term functioning and need psychosocial support as part of recovery.
Choosing and Monitoring an Antipsychotic
First-generation drugs include haloperidol and chlorpromazine. Second-generation drugs include olanzapine, risperidone, quetiapine and aripiprazole. Select collaboratively based on benefit, physical health, interactions, prior response and which adverse effects the patient finds most difficult.
Dopamine receptor blockade can reduce positive symptoms. It can also cause movement disorders via nigrostriatal effects. Dopamine normally inhibits prolactin release, so blockade can cause hyperprolactinaemia, with amenorrhoea, galactorrhoea, sexual dysfunction or adverse effects on bone health when prolonged. Antipsychotics differ in receptor effects. Aripiprazole acts as a partial agonist at and serotonin receptors and as an antagonist at receptors.
| Example | Adverse effects that can influence choice |
|---|---|
| Haloperidol | Dystonia, akathisia, parkinsonism and QT prolongation. Review the product ECG requirements and QT-related interactions. |
| Risperidone | Prolactin elevation and dose-related movement effects. New galactorrhoea or sexual dysfunction warrants review. |
| Olanzapine and clozapine | Weight gain and metabolic effects. Clozapine also requires a dedicated safety monitoring service. |
| Quetiapine | Somnolence and postural hypotension, particularly during initiation or titration. |
| Aripiprazole | Ask about akathisia even when metabolic or prolactin concerns influence the decision to use it. |
Initial and follow-up checks
Under the named adult NICE CG178 recommendations, record weight, waist circumference, pulse and BP, fasting glucose or HbA1c, lipids, prolactin, pre-existing movement symptoms, diet and physical activity before starting. Obtain a baseline ECG when required by the product information, with specified cardiovascular risk or cardiovascular disease, or when the person is being admitted. In Ireland, check the relevant product information and local monitoring protocol.
NICE recommends weighing weekly for six weeks, then at 12 weeks, one year and annually. Recheck BP, pulse, glycaemia and lipids at 12 weeks, one year and annually, and waist annually. During titration ask about effects that change adherence or safety, including sedation, postural dizziness and restlessness. Early follow-up also establishes whether symptoms and functioning are improving. Psychological and family interventions complement drug treatment in first-episode psychosis.
Antipsychotic-Associated Movement Disorders
| Presentation | Clues | Immediate or subsequent clinical decision |
|---|---|---|
| Acute dystonia | Painful sustained eye, jaw or neck contraction, often in the first hours to days after starting or increasing a dopamine blocker. Stridor or difficulty swallowing can signal airway involvement. | Assess the airway promptly and summon help for respiratory or bulbar symptoms. Treat promptly with a locally available parenteral antimuscarinic under the acute medicines protocol. Review the culprit drug and the need for short-term cover against recurrence. |
| Akathisia | Inner restlessness with pacing, shifting position or inability to sit comfortably. Can emerge early during treatment or after dose changes. | Ask specifically about the urge to move so it is not mistaken for psychotic agitation. Reassess the dose or switch with psychiatry. Propranolol is an option for selected patients after checking BP, pulse and contraindications. |
| Drug-induced parkinsonism | Bradykinesia, rigidity and sometimes tremor, often developing over weeks. | Consider a dose reduction or switch with psychiatry. A short course of an oral antimuscarinic may help selected patients. Consider cognitive, bowel and urinary harms. |
| Tardive dyskinesia | Repetitive involuntary movements, often of the tongue, mouth or jaw, after longer exposure. Movements can persist after the drug is changed. | Review the antipsychotic and other drugs with the specialist. Antimuscarinics can aggravate the movements. The APA guideline recommends a VMAT2 inhibitor for moderate to severe or disabling cases, with treatment choice and access determined by the specialist. |
These time courses overlap. The pattern of movement and its relationship to drug exposure are more helpful than a fixed clock. Ask about dopamine-blocking antiemetics as well as antipsychotics.
Neuroleptic malignant syndrome
Neuroleptic malignant syndrome (NMS) is a potentially life-threatening reaction to dopamine blockade, including antipsychotics and some antiemetics. An NMS-like emergency can also follow abrupt withdrawal of dopaminergic therapy. Look for altered consciousness, widespread rigidity, hyperthermia and autonomic instability. Review recent starts, dose changes and depot preparations. Onset is commonly over days. Some cases, particularly with certain second-generation antipsychotics, have less typical findings.
Distinguish NMS from serotonin toxicity
| Feature | NMS | Serotonin toxicity |
|---|---|---|
| Exposure | Dopamine blockade or abrupt loss of dopaminergic therapy | Recent serotonergic exposure, interaction, dose increase or overdose |
| Neuromuscular findings | Generalised sustained rigidity, often described as lead-pipe. Clonus is less characteristic. | Clonus, hyperreflexia and tremor are characteristic. Severe rigidity can obscure the findings. |
| Time course | Often days after a change, depending on the exposure | Often rapid after a relevant exposure, with variations by drug and interaction |
| Investigations | Raised creatine kinase and leukocytosis may support the picture. Assess for rhabdomyolysis and kidney injury. | Severe muscle activity and hyperthermia can also cause rhabdomyolysis. Exposure and examination help distinguish the syndromes. |
| Immediate treatment principle | Stop dopamine blockers and provide urgent monitored support. Obtain specialist advice on adjuncts. | Stop the serotonergic agents, stabilise the patient, control muscle activity and cool if hyperthermic. |
Exclude other causes such as infection, malignant catatonia and heat-related illness as appropriate. Do not let a laboratory test delay emergency management. Check CK, ECG, electrolytes and renal function and monitor complications such as hyperkalaemia, aspiration and acute kidney injury.
Emergency management
- Stop dopamine-blocking medicines including further doses of depot antipsychotics, and review other medicines with the treating team. If a dopaminergic medicine has been withdrawn, seek specialist advice promptly on reinstatement.
- Stabilise airway, breathing and circulation. Use active cooling when indicated and obtain urgent critical care input for severe manifestations. Give isotonic crystalloid guided by perfusion, urine output, kidney function and volume status. Treat complications. Routine bicarbonate to alkalinise urine is not recommended for prevention of rhabdomyolysis-associated kidney injury.
- Discuss adjunctive treatment with specialists. Benzodiazepines, bromocriptine or amantadine, dantrolene, or ECT may be considered according to severity, rigidity, temperature and response. Dantrolene acts on skeletal muscle. It is not a dopamine agonist.
Worked distinction: After an antipsychotic change, marked rigidity, reduced consciousness, autonomic instability and a raised CK are consistent with NMS. Stopping the implicated medicines, assessing airway and perfusion, cooling and managing rhabdomyolysis take priority.
Clozapine for Treatment-Resistant Schizophrenia
Consider clozapine with the specialist team when schizophrenia has not improved adequately despite two appropriate antipsychotic trials with adequate doses, durations and adherence. The Irish Leydex authorisation includes at least one atypical antipsychotic in those trials. It also permits use for severe, untreatable neurological reactions to other antipsychotics in schizophrenia and for psychosis in Parkinson disease after standard strategies fail. Check drug and substance use and other reasons for apparent non-response. Register the patient with the current brand's monitoring service.
Absolute neutrophil count and urgent illness
The July 2026 Irish Leydex product information uses absolute neutrophil count (ANC). Check the current Irish information and the named monitoring service for the product prescribed. For Leydex the starting ANC is at least generally, or with confirmed benign ethnic neutropenia (BEN) and haematology agreement.
- Routine checks: Weekly for the first 18 weeks, then monthly through year one. After a year without neutropenia, monitor every 12 weeks. After two years without neutropenia, monitor annually. After complete discontinuation, monitor weekly for four weeks under the service protocol, with daily testing until recovery when a low ANC prompted cessation. Check the schedule after a temporary interruption with the service.
- Low ANC without BEN: At to below , monitor twice weekly until stable or improving and then monthly. Below , stop after the first result, check counts daily until recovery and do not re-expose.
- Confirmed BEN: At to below , monitor twice weekly until stable or improving before returning to monthly checks. Below , stop immediately, monitor daily until recovery and do not re-expose.
- Fever, sore throat or mouth ulcers: Assess urgently and obtain an immediate differential count. Start emergency evaluation and empiric IV antibiotics under the local protocol if febrile neutropenia with suspected sepsis is present. Notify the clozapine monitoring service and coordinate with psychiatry and haematology. Clinical urgency depends on the patient's condition and ANC trend as well as the drug stop threshold.
Other urgent complications
- Myocarditis or cardiomyopathy: Suspect it with persistent resting tachycardia, chest pain, unexplained breathlessness or other heart failure symptoms, especially in the first two months. Stop clozapine promptly and arrange immediate cardiac assessment when suspected. Use local cardiac monitoring and investigation protocols.
- Gastrointestinal hypomotility: Ask specifically about stool frequency and treat constipation actively. Review other constipating medicines and individualise prevention. Abdominal pain or distension with vomiting or failure to pass stool or flatus can indicate obstruction or ileus and warrants urgent assessment.
- Seizures: Risk increases with dose. Seek specialist review of dose and antiseizure treatment after a seizure. Avoid carbamazepine with clozapine because of bone marrow suppression. Abrupt smoking cessation can increase clozapine exposure, so tell the prescribing team if smoking changes.
- Interrupted dosing: With Leydex, after more than two days without a dose, restart through the prescribing team at 12.5 mg once or twice on the first day and retitrate. The prior maintenance dose can cause marked hypotension and other acute problems if restarted directly.
A 22-year-old man is admitted after a first presentation of persecutory psychosis and starts oral haloperidol. The next day his neck turns forcefully to the right and his eyes roll up. He is alert and in pain, with sustained muscle contractions and no fever, stridor or difficulty swallowing. What is the most appropriate immediate treatment?
Give oral propranolol and reassess in 48 hours
Treat this as an anxiety-related tic with grounding exercises
Give intravenous dantrolene for neuroleptic malignant syndrome
Give an available parenteral antimuscarinic under the local acute medicines protocol
A 38-year-old man with chronic schizophrenia on zuclopenthixol depot and oral haloperidol is reviewed in the medical assessment unit after being found semi-conscious in his hostel. His vital signs show a temperature of 39.8°C, pulse 132 beats/min, blood pressure 184/108 mmHg, and respiratory rate 26 breaths/min with profuse generalized diaphoresis. On physical examination, he is stuporous, muttering incomprehensibly, and displays extreme, generalized 'lead-pipe' rigidity across all limbs. Reflexes are globally diminished, and there is no clonus. Laboratory investigations reveal: Haemoglobin 14.8 g/dL, White blood cells 18.4 x 10^9/L, Platelets 340 x 10^9/L, Creatine Kinase 24,500 U/L (reference <200 U/L), Urea 14.2 mmol/L, Creatinine 210 micromol/L. What is the most appropriate primary clinical management strategy?
Prescribe oral cyproheptadine and administer active antipyretic therapy with intravenous paracetamol
Stop all dopamine blockers, stabilise and cool in a monitored critical care setting, and treat rhabdomyolysis with reassessed fluid resuscitation
Increase the haloperidol dose to suppress worsening acute psychotic agitation and add oral fluoxetine
Treat this as uncomplicated dystonia with an antimuscarinic and continue the antipsychotics
A 29-year-old woman taking Leydex clozapine for treatment-resistant schizophrenia presents after nine weeks of therapy. She has shivering, a severe sore throat and a temperature of 38.6°C. Her absolute neutrophil count is 0.9 × 10⁹/L. She has no history of benign ethnic neutropenia. What is the immediate management?
Switch to chlorpromazine and discharge with a monthly count
Increase the clozapine dose and add carbamazepine
Stop clozapine, manage suspected neutropenic sepsis urgently and contact haematology and the monitoring service
Prescribe oral amoxicillin and continue clozapine pending a repeat count
Sections you finish are checked off in the contents.